Inoperable recurrent rectal cancer: Results of a prospective trial with radiation therapy and razoxane

Rhomberg, Walter; Eiter, Helmut; Hergan, Klaus; Schneider, Barbara

doi:10.1016/0360-3016(94)90023-x

Cited by 31 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That was described earlier [30] and is confirmed in this small study. The better local control is probably due to the G2/M arrest in the cell cycle induced by razoxane, which is the phase most sensitive to irradiation.…”

Section: Resultssupporting

confidence: 80%

“…Earlier studies using razoxane together with radiotherapy showed rather high local control rates, and survival data which compared favorably with results from the literature [29,30]. Therefore, a randomized study was initiated by the Austrian Society for Radiooncology (ÖGRO) in 1992.…”

Section: Introductionsupporting

confidence: 58%

“…In our study, in group A only one patient (7%) had a previous treatment with 5-FU for 5 days, whereas in group B eight of 18 patients (44%) were pretreated by 5-FU-based regimens. This may also be the reason why the response rate achieved with radiotherapy and razoxane in this study (39%) was not as high as in the previous phase II study (57%) [30].…”

Section: Discussionmentioning

confidence: 51%

“…In a phase II study using radiotherapy together with razoxane for recurrent nonmetastatic rectal cancer [30], a median survival of 24 months was observed whereas a historical control group with radiotherapy alone showed a survival of 12 months. A median survival around 12 months was a common value in the literature until 1994, even for combination chemoradiotherapy with 5-FU-based regimens [4,6,7,11,27,39].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer

Rhomberg

Hammer²,

Sedlmayer

et al. 2007

Strahlenther Onkol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 80%

Section: Introductionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer

Rhomberg

Hammer²,

Sedlmayer

et al. 2007

Strahlenther Onkol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Radiotherapy alone or in combination with chemotherapy palliates patients with recurrent disease, but long-term survival is not expected. Furthermore, 5-year survival is approximately 5% without surgical intervention [7][8][9], and palliative surgery alone prolongs mean survival to about 11 months [10,11]. In previous literature, radical resection of the locally recurrent tumors and achieving microscopically negative margins can offer the only chance for long-term survival, 12% to 33% of 5-year survival, but a high rate of perioperative morbidity is still a concern [12][13][14][15].…”

Section: Introductionmentioning

confidence: 98%

Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection

Park

Kim

Hur

et al. 2008

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma

Valentini

Morganti

Franco

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND Rectal carcinoma patients with local recurrence are reported to have a dismal prognosis. The purpose of this study was to evaluate the effect of combined modality therapy on clinical outcome and to determine the prognostic impact of a “presurgical” staging system. METHODS Between September 1989 and June 1997, 47 patients (with a median follow‐up of 80 months) with locally recurrent, nonmetastatic rectal carcinoma were classified according to the extent of pelvic sidewall involvement as determined by pretreatment computed tomography (CT) scan. They received preoperative external beam radiation (45–47 grays [Gy] in 34 patients; 23.4 Gy in 13 preirradiated patients) plus concomitant 5‐fluorouracil (1000 mg/m2/day as a 96‐hour continuous infusion on Days 1–4 + 29–32) and mitomycin C (10 mg/m2 as a bolus intravenously on Day 1 + 29). After 4–6 weeks, the patients were evaluated for surgical resection and intraoperative radiation therapy (IORT) procedure (10–15 Gy) or, in unresectable patients, a boost dose was planned by chemoradiation (23.4 Gy) or brachytherapy. Thereafter, adjuvant chemotherapy (5‐fluorouracil and leucovorin for a total of six to nine courses) was prescribed. RESULTS During chemoradiation, 2 patients (4.3%) developed Radiation Therapy Oncology Group Grade 3–4 acute toxicity. Twenty‐five patients (53.2%) had an objective response after chemoradiation. Twenty‐one patients (45%) underwent radical surgical resection. The overall 5‐year survival and local control rates were 22% and 32%, respectively. The classification system significantly predicted survival (P = 0.008). Radically resected patients had better local control and survival (P < 0.0001); in patients treated with IORT, the 5‐year local control and survival rates were 79% and 41%, respectively. CONCLUSIONS The data from the current study suggest that combined modality therapy was well tolerated and improved resectability, local control, and survival. The classification system appears to be a reliable tool with which to predict clinical outcome in patients with locally recurrent rectal carcinoma. Cancer 1999;86:2612–24. © 1999 American Cancer Society.

show abstract

Inoperable recurrent rectal cancer: Results of a prospective trial with radiation therapy and razoxane

Cited by 31 publications

References 19 publications

Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer

Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer

Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection

Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma

Contact Info

Product

Resources

About